<DOC>
	<DOCNO>NCT01537666</DOCNO>
	<brief_summary>The study carry evaluate safety , tolerability pharmacokinetics AeroVanc inhalation powder healthy volunteer , patient cystic fibrosis .</brief_summary>
	<brief_title>Inhaled Vancomycin Tolerability , Safety Pharmacokinetics</brief_title>
	<detailed_description>The study three main objective : - To evaluate safety , tolerability AeroVanc inhalation powder healthy volunteer , patient CF . - To determine systemic bioavailability vancomycin healthy volunteer follow single dose pulmonary administration 16 mg , 32 mg , 80 mg dos AeroVanc comparison 250 mg dose vancomycin administer intravenously . - To estimate lung sputum concentration vancomycin patient cystic fibrosis ( CF ) follow single dose pulmonary administration 32 mg 80 mg dos AeroVanc .</detailed_description>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Inclusion Criteria Healthy Volunteers : 1 . Healthy male volunteer 18 50 year age inclusive . 2 . Able communicate site personnel understand voluntarily sign Informed Consent Form . 3 . Able willing comply Protocol , include availability schedule study visit . 4 . Body Mass Index ( BMI ) 20 30 kg/m2 inclusive , weight 6090 kg inclusive . 5 . No clinically significant abnormality screen determine medical history , physical examination , blood chemistry , hematology , urinalysis , 12lead ECG . Negative urine screen drug abuse negative alcohol breath test Screening prior dosing . 6 . Negative human immunodeficiency virus ( HIV ) Hepatitis B Hepatitis C screen test result . 7 . Spirometry ( forced expiratory volume 1 second ( FEV1 ) ) value screen great 75 % predict ageadjusted value . Exclusion Criteria Healthy Volunteers : 1 . A history pulmonary disorder likely influence drug absorption . 2 . Evidence suspicion clinically significant respiratory , renal , hepatic , central nervous system , cardiovascular metabolic dysfunction . 3 . A history previous allergy sensitivity vancomycin , component ( ) study drug reference drug . 4 . Smokers ( exsmokers quit smoke must one year period smoking prior study drug administration ) . 5 . Respiratory tract infection within last two week prior first study drug administration . 6 . Treatment prescription medication and/or overthecounter ( OTC ) product include vitamin mineral supplement within 48 hour Investigational Product administration . 7 . Vaccination within one month study drug administration . 8 . Systolic blood pressure &lt; 110 mmHg &gt; 150 mmHg inclusive diastolic blood pressure &lt; 60 mmHg &gt; 90 mmHg inclusive . 9 . A history drug alcohol abuse . 10 . Participation clinical study within three month Investigational Product administration . 11 . Donation blood plasma within three month Investigational Product administration . 12 . Any condition view Investigator likely interfere study put subject risk . Inclusion Criteria CF Patients : 1 . Able communicate site personnel understand voluntarily sign Informed Consent Form . 2 . Able willing comply protocol , include availability schedule study visit . 3 . Have confirm diagnosis cystic fibrosis ( two establish method , e.g . positive sweat chloride value ≥ 60 mEq/L , nasal potential difference test , and/or genotype two identifiable mutation consistent CF , accompany one clinical feature consistent CF phenotype ) . 4 . Be age ≥ 18 year old 5 . Have FEV1 &gt; 40 % predict 6 . Be able perform technique necessary measure lung function 7 . No liver enzyme increase twice upper limit normal 8 . Ability spontaneously produce bronchial sputum daily Inclusion Criteria CF Patients : 1 . Administration investigational drug device within 28 day Screening within six halflives investigational drug . 2 . Oral corticosteroid dose exceed 10 mg per day 16 mg every day . 3 . History sputum culture throat swab culture yield B. cepacia previous two year . 4 . History positive MRSA culture , sputum culture positive MRSA screening . 5 . Current daily continuous oxygen supplementation requirement 2 L/min night . 6 . A history previous allergy sensitivity vancomycin , component ( ) study drug . 7 . Changes antimicrobial , bronchodilator , antiinflammatory corticosteroid medication within 7 day prior Screening . 8 . Changes physiotherapy technique schedule within 7 day prior Screening . 9 . History lung transplantation . 10 . A chest XRay Screening within previous 90 day Screening , abnormalities indicate significant acute finding ( e.g. , lobar infiltrate atelectasis , pneumothorax , pleural effusion ) . 11 . Positive pregnancy test . All woman childbearing potential test . 12 . Female childbearing potential lactating practice acceptable method birth control ( e.g. , hormonal barrier method , intrauterine device ) . 13 . Findings Screening , investigator 's opinion , would compromise safety subject quality study data . 14 . History severe cough/bronchospasm upon inhalation dry powder inhalation product . 15 . Considered `` terminally ill '' eligible lung transplantation . 16 . Have significant episode hemoptysis ( &gt; 60 mL ) three month prior enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>